Condensed Consolidated Statements of Operation - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue:
Testing revenue	$ 10,604	$ 7,902
Product revenue	3,307	3,667
License and other revenue	142	15
Total revenue	14,053	11,584
Operating expenses:
Cost of testing	4,112	3,057
Cost of product	2,272	2,327
Research and development	3,368	3,283
Sales and marketing	4,085	3,222
General and administrative	5,307	6,502
Goodwill impairment	0	1,958
Change in estimated fair value of contingent consideration	144	(221)
Total operating expenses	19,288	20,128
Loss from operations	(5,235)	(8,544)
Interest expense	(2,695)	(790)
Other expense, net	(2,809)	(686)
Change in estimated fair value of common stock warrant liability and derivative liability	1,321	4,128
Loss before income taxes	(9,418)	(5,892)
Income tax benefit	424	283
Net loss	(8,994)	(5,609)
Net loss attributable to noncontrolling interest	(25)	(47)
Net loss attributable to CareDx, Inc.	$ (8,969)	$ (5,562)
Net loss per share attributable to CareDx, Inc. (Note 3):
Basic	$ (0.30)	$ (0.26)
Diluted	$ (0.30)	$ (0.26)
Weighted average shares used to compute net loss per share attributable to CareDx, Inc.:
Basic	29,615,441	21,343,782
Diluted	29,615,441	21,343,782